POTELIGEO® approved by the FDA

POTELIGEO® approved by the FDA

The U.S. Food and Drug Administration has approved a new treatment for two rare types of non-Hodgkin lymphoma: Poteligeo® (mogamulizumab-kpkc). Poteligeo® has been approved to treat adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

Read more

Previous

Next